| Jacob A Thomas, MD | |
|
1000 Mineral Point Ave, Janesville, WI 53548-2940 | |
| (608) 756-6741 | |
| (608) 756-6376 |
| Full Name | Jacob A Thomas |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 15 Years |
| Location | 1000 Mineral Point Ave, Janesville, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053540021 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | ML60093008 (Washington) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 55438-20 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Valley Medical Center | Renton, WA | Hospital |
| Multicare Auburn Medical Center | Auburn, WA | Hospital |
| Tacoma General Allenmore Hospital | Tacoma, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vantage Radiology And Diagnostic Services, A Professional Services Cor | 8224937917 | 37 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
In groundbreaking new research, mechanical engineers and computer scientists at the University of Minnesota have developed a 3D printing technique that uses motion capture technology, similar to that used in Hollywood movies, to print electronic sensors directly on organs that are expanding and contracting.
Today's smartphones allow for increased opportunities for activities traditionally defined as sedentary behaviors, such as surfing the internet, emailing and playing video games. However, researchers Jacob Barkley and Andrew Lepp, faculty members in the College of Education, Health and Human Services at Kent State University, linked high cell phone use to poor fitness in college students.
Just as militaries need to have trained, experienced soldiers ready for future wars, making sure that the immune system has enough battle-ready T cells on hand is important for fast-acting, more effective vaccines, according to Penn State researchers.
› Verified 9 days ago
| Entity Name | Vantage Radiology & Diagnostic Services, A Professional Services Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245230598 PECOS PAC ID: 8224937917 Enrollment ID: O20031231000620 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
In groundbreaking new research, mechanical engineers and computer scientists at the University of Minnesota have developed a 3D printing technique that uses motion capture technology, similar to that used in Hollywood movies, to print electronic sensors directly on organs that are expanding and contracting.
Today's smartphones allow for increased opportunities for activities traditionally defined as sedentary behaviors, such as surfing the internet, emailing and playing video games. However, researchers Jacob Barkley and Andrew Lepp, faculty members in the College of Education, Health and Human Services at Kent State University, linked high cell phone use to poor fitness in college students.
Just as militaries need to have trained, experienced soldiers ready for future wars, making sure that the immune system has enough battle-ready T cells on hand is important for fast-acting, more effective vaccines, according to Penn State researchers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacob A Thomas, MD 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 756-6741 | Jacob A Thomas, MD 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 756-6741 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
In groundbreaking new research, mechanical engineers and computer scientists at the University of Minnesota have developed a 3D printing technique that uses motion capture technology, similar to that used in Hollywood movies, to print electronic sensors directly on organs that are expanding and contracting.
Today's smartphones allow for increased opportunities for activities traditionally defined as sedentary behaviors, such as surfing the internet, emailing and playing video games. However, researchers Jacob Barkley and Andrew Lepp, faculty members in the College of Education, Health and Human Services at Kent State University, linked high cell phone use to poor fitness in college students.
Just as militaries need to have trained, experienced soldiers ready for future wars, making sure that the immune system has enough battle-ready T cells on hand is important for fast-acting, more effective vaccines, according to Penn State researchers.
› Verified 9 days ago
Joshua L. Orwig, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6741 Fax: 608-756-6376 | |
Dr. James G. Kirschbaum, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6741 Fax: 608-756-6376 | |
Dr. Ananthakrishna Chilukuri, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 230 S Wright Rd, Janesville, WI 53546 Phone: 952-595-1100 Fax: 612-294-4903 | |
Bart J. Schmidt, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6741 Fax: 608-756-6376 | |
Dr. Michael J Garcia, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 907 Cambridge Dr, Janesville, WI 53548 Phone: 608-758-8976 | |
Dr. Gregory L Denison, MD Radiology Medicare: Medicare Enrolled Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6000 | |
Dr. James A Hanson, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6741 Fax: 608-756-6376 |